Filtered By:
Condition: Hypertrophic Cardiomyopathy
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 437 results found since Jan 2013.
Stroke and Embolic Events in Hypertrophic Cardiomyopathy: Risk Stratification in Patients Without Atrial Fibrillation Clinical Sciences
Conclusions—
The incidence of stroke and embolic events was about 1.0% per year in the HCM cohort. AF had not been previously documented before the event in more than half of patients with events. Older age and enlarged left atrial dimension are possible risk factors for embolic events in patients with HCM without documented AF.
Source: Stroke - March 27, 2016 Category: Neurology Authors: Haruki, S., Minami, Y., Hagiwara, N. Tags: Cerebrovascular Disease/Stroke Clinical Sciences Source Type: research
Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study.
This study aimed to determine the incidence of stroke and its risk factors in HCM patients with AF during a long-term follow-up. Using a national database, we retrospectively investigated 18,724 HCM patients from a systematic sample of 1,000,000 Taiwanese people between 1997 and 2013. The incidences of AF and stroke were estimated. Data were analyzed using Cox regression models. AF was identified in 598 patients (262 men, mean age 66.3±13.0 years) during a median follow-up of 7.0 years. The AF incidence in HCM patients was 5.83 per 1000 person-years, and the overall incidence of AF-associated stroke was 24.14 per 1000 per...
Source: Aging - November 23, 2020 Category: Biomedical Science Authors: Hsu JC, Huang YT, Lin LY Tags: Aging (Albany NY) Source Type: research
Hypertrophic Cardiomyopathy in Patients with Atrial Fibrillation: Prevalence and Associated Stroke Risks in a Nationwide Cohort Study.
CONCLUSION: Among all NVAF patients, 1.1% of patient has HCM. The risk of stroke in NVAF with HCM without any CHA2DS2-VASc stroke risk factors was similar to that of those patients without HCM with CHA2DS2-VASc score of 3. Despite this, the actual use of OACs among NVAF patients with HCM was sub-optimal, relative to their high stroke risk.
PMID: 30602200 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 2, 2019 Category: Hematology Authors: Jung H, Yang PS, Sung JH, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Pak HN, Lee MH, Lip GYH, Joung B Tags: Thromb Haemost Source Type: research
Left ventricular hypertrophy diagnosed after a stroke: a case report
ConclusionsElectrocardiogram diagnosis of left ventricular hypertrophy led to the diagnosis of apical hypertrophic cardiomyopathy in this patient. Left ventricular hypertrophy was only evident a few days after our patient suffered a stroke. The underlying mechanisms responsible for this remain unclear. Furthermore, differential diagnosis of hypertrophic cardiomyopathy should be considered in people with electrocardiogram criteria for left ventricular hypertrophy. Cardiovascular magnetic resonance imaging is an important diagnostic tool in identifying causes of left ventricular hypertrophy. Family screening should be recomm...
Source: Journal of Medical Case Reports - March 22, 2018 Category: General Medicine Source Type: research
Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology
ConclusionsThe study reveals a high prevalence and diverse distribution of AF in patients with cardiomyopathies, inadequate anticoagulation regimen, and high risk of stroke/TIA in this population.
Source: ESC Heart Failure - September 16, 2020 Category: Cardiology Authors: Katarzyna Mizia ‐Stec,
Alida L.P. Caforio,
Philippe Charron,
Juan R. Gimeno,
Perry Elliott,
Juan Pablo Kaski,
Aldo P. Maggioni,
Luigi Tavazzi,
Angelos G. Rigopoulos,
Cecile Laroche,
Attila Frigy,
Elisabetta Zachara,
Maria Luisa Pena‐Pena, Tags: Original Research Article Source Type: research
The real world of stroke incidence in patients with hypertrophic cardiomyopathy
We have read a paper with great interest written by Fumagalli and colleagues concerning “the incidence of stroke in patients with hypertrophic cardiomyopathy (HCM) among different heart rhythm” [1]. In this paper, the authors found that stroke rates in HCM patients no prior history of atrial fibrillation (AF), stroke rates were similar in those with de novo AF or stable sinus rate (SR). And they further observed that severe left atrium dilatation was a powerful risk factor, irrespective of AF. The results provided evidence for the anticoagulation strategies to prevent stroke in patients with HCM.
Source: International Journal of Cardiology - July 7, 2023 Category: Cardiology Authors: Xinru Chen Tags: Letter to the Editor Source Type: research
Incidence of ischemic stroke and systemic embolism in patients with hypertrophic cardiomyopathy, nonvalvular atrial fibrillation, CHA 2 DS 2 -VASc score of ≤1 and without anticoagulant therapy
Abstract
Data on the risk of ischemic stroke and systemic embolism (iSSE) events in patients with nonvalvular atrial fibrillation (NVAF), a CHA2DS2-VASc score of ≤1, hypertrophic cardiomyopathy (HCM), and without anticoagulant therapy are still lacking. The aim of this study was to investigate the incidence of iSSE events in these patients. We consecutively screened medical records of patients with HCM and NVAF referred to Fuwai Hospital between January 1994 and March 2014. The primary end point was iSSE events, defined as a composite of ischemic stroke and systemic embolism. Follow-up was carried out to ascert...
Source: Heart and Vessels - July 31, 2015 Category: Cardiology Source Type: research
The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants.
Abstract
The last ten years have seen rapid strides in the evolution of nonvitamin K oral anticoagulants (NOACs) for stroke prevention in patients with atrial fibrillation (AF). For the preparation of this consensus, a comprehensive literature search was performed and data on available trials, subpopulation analyses, and case reports were analyzed. This Indian consensus document intends to provide guidance on selecting the right NOAC for the right patients by formulating expert opinions based on the available trials and Asian/Indian subpopulation analyses of these trials. A section has been dedicated to the curren...
Source: Indian Heart J - December 1, 2015 Category: Cardiology Authors: Dalal J, Bhave A, Oomman A, Vora A, Saxena A, Kahali D, Poncha F, Gambhir DS, Chaudhuri JR, Sinha N, Ray S, Iyengar SS, Banerjee S, Kaul U, SPAF Academy India experts Tags: Indian Heart J Source Type: research
Author's reply to Atrial fibrillation patients with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
We thank Dr. Joung and colleagues for their interests in our work.1 In our study, patients with non-valvular atrial fibrillation (NVAF) with hypertrophic cardiomyopathy (HCM) had a higher risk of stroke than NVAF patients without HCM in all generations and all CHA2DS2-VASc score groups. As shown in the study of Jung et al.,2 the stroke risk in NVAF with HCM without any other stroke risk factor was greater than that in NVAF with a CHA2DS2-VASc score of 2. We agree with their results, and all NVAF patients with HCM should receive anticoagulation.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Toyonobu Tsuda, Akihiro Nomura, Kenshi Hayashi Source Type: research
Reply to the Editor — Patients with atrial fibrillation with hypertrophic cardiomyopathy: Do we need new stroke risk stratification?
We thank Joung et al for their interest in our work.1 In our study, patients with nonvalvular atrial fibrillation (NVAF) with hypertrophic cardiomyopathy (HCM) had a higher risk of stroke than did patients with NVAF without HCM in all generations and all CHA2DS2-VASc score groups. As shown in the study by Jung et al,2 stroke risk in patients with NVAF with HCM without any other stroke risk factor was higher than that in patients with NVAF with a CHA2DS2-VASc score of 2. We agree with their results, and all patients with NVAF with HCM should receive anticoagulation.
Source: Heart Rhythm - April 3, 2019 Category: Cardiology Authors: Toyonobu Tsuda, Akihiro Nomura, Kenshi Hayashi Source Type: research
Stroke and Bleeding Risk Assessment in Atrial Fibrillation: Where Are We Now?
Korean Circ J. 2021 Jun 1. doi: 10.4070/kcj.2021.0170. Online ahead of print.ABSTRACTMost important international guidelines recommend the use of CHA₂DS₂-VASc and HAS-BLED scores for stroke and bleeding risk assessments in atrial fibrillation (AF) patients, respectively. The 2020 AF guidelines of European Society of Cardiology have revised the definition of "C: congestive heart failure (HF)" component, and now patients with either HF with reduced ejection fraction or preserved ejection fraction should be assigned 1 point. Hypertrophic cardiomyopathy was also included. Besides, the revised "V: vascular diseases" compone...
Source: Korean Circulation Journal - July 6, 2021 Category: Cardiology Authors: Ling Kuo Yi Hsin Chan Jo Nan Liao Shih Ann Chen Tze Fan Chao Source Type: research
